Skull Smash LLC sold unapproved, misbranded ammonia inhalant stimulant drugs online, FDA says.
What happened
FDA reviewed Skull Smash's website on November 16, 2023, and its Facebook account on November 20, 2023, and found the ammonia inhalant products available for purchase in the United States. FDA concluded the products are unapproved new drugs and misbranded. FDA said the products are intended as stimulant drugs, contain ammonium carbonate, and are labeled for intranasal use.
What FDA found
Label and website claims show the products are intended to affect body function and act as stimulant drugs.
section 201(g)(1)(B)/(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B)/(C); 21 CFR 201.128The ammonia inhalant products are new drugs marketed without an FDA-approved application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)As reflex stimulants, the ammonia products are deemed new drugs because FDA has proposed that ammonia reflex stimulants are not generally recognized as safe and effective.
section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4); 73 FR 34895Even as general stimulants, the products do not meet OTC Monograph M011 because they use ammonium carbonate and intranasal directions, while M011 allows only oral caffeine.
section 505G of the FD&C Act, 21 U.S.C. 355h; OTC Monograph M011The products are misbranded because they are nonprescription drugs that do not meet section 505G and have no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
What FDA wants
FDA asks Skull Smash to respond in writing within 15 working days, saying what it has done to correct the violations and prevent recurrence; if it cannot finish, it must give reasons and a completion schedule.
Who should pay attention
- retailers and online marketplaces selling ammonia inhalants
- strength sports and gym suppliers promoting smelling salts
- brands selling OTC stimulant inhalants without an approved application
This is a summary. Read the original letter on fda.gov.